SCLX Scilex Holding Company - Common Stock
$6.36
Price · Aug 19, 2026
Fundamentals as of May 20, 2026
52W Range
$4–$34
7% of range
Analyst Rating
HOLD
6 analysts
Price Target
—
P/E (TTM)
—
ROE
—
Net Profit Margin
—
SCLX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$6.36
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$4 – $34
SCLX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
SCLX
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
SCLX
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
SCLX
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
SCLX
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
SCLX
Peer Median
SCLX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
SELL
6 analysts
- Strong Buy 0 0.0%
- Buy 0 0.0%
- Hold 3 50.0%
- Sell 1 16.7%
- Strong Sell 2 33.3%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-2.3%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-4.76 | — | — |
| Dec. 31, 2025 | $-2.21 | $-0.48 | -1.7% |
| Sept. 30, 2025 | $-21.05 | $-0.84 | -20.2% |
| June 30, 2025 | $-3.79 | $-0.93 | -2.9% |
| March 31, 2025 | $-2.26 | $-1.25 | -1.0% |
| Dec. 31, 2024 | $0.00 | $-6.96 | 7.0% |
| Sept. 30, 2024 | $-1.05 | $-5.95 | 4.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 16
| Metric | Trend | Q1 2026 | Q1 2025 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $9M | $5M | $16M | |
| Cost of Revenue | $17M | $13M | $4M | |
| Gross Profit | $26M | $18M | · | |
| R&D Expense | $3M | $2M | $2M | |
| SG&A Expense | $31M | $28M | $25M | |
| Operating Income | $-32M | $-28M | $-16M | |
| Interest Expense | · | · | $571.0K | |
| Other Non-op | $-13M | $2M | · | |
| Pretax Income | $-46M | $-26M | $-38M | |
| Income Tax | · | · | $0 | |
| Net Income | $-46M | $-26M | $-38M | |
| EPS (Basic) | $-6.28 | $-2.26 | $-0.31 | |
| EPS (Diluted) | $-6.28 | $-2.26 | $-0.31 | |
| Shares (Basic) | 6,891,000 | 11,565,000 | 120,188 | |
| Shares (Diluted) | 6,891,000 | 11,565,000 | 120,188 | |
| EBITDA | $-29M | · | $-16M |
Balance Sheet 23
| Metric | Trend | Q1 2026 | Q1 2025 | Q2 2024 |
|---|---|---|---|---|
| Cash & Equivalents | $3M | · | $7M | |
| Receivables | $11M | · | $38M | |
| Inventory | $5M | · | $3M | |
| Current Assets | $42M | · | $50M | |
| PP&E (Net) | $13M | · | $714.0K | |
| PP&E (Gross) | $14M | · | $753.0K | |
| Accum. Depreciation | $1M | · | $39.0K | |
| Goodwill | $13M | · | $13M | |
| Intangibles | $60M | · | $34M | |
| Total Assets | $294M | · | $105M | |
| Accounts Payable | $102M | · | $42M | |
| Current Liabilities | $502M | · | $255M | |
| Capital Leases | $13M | · | $2M | |
| Other Non-current Liabilities | $177.0K | · | $187.0K | |
| Total Liabilities | $548M | · | $319M | |
| Common Stock | $1.0K | · | $18.0K | |
| Paid-in Capital | $799M | · | $426M | |
| Retained Earnings | $-965M | · | $-552M | |
| Treasury Stock | $77M | · | $91M | |
| AOCI | $-7M | · | $2M | |
| Stockholders' Equity | $-249M | · | $-215M | |
| Liabilities + Equity | $294M | · | $105M | |
| Shares Outstanding | 8,491,267 | · | 121,405,037 |
Cash Flow 9
| Metric | Trend | Q1 2026 | Q1 2025 | Q2 2024 |
|---|---|---|---|---|
| D&A | $3M | $1M | · | |
| Stock-based Comp | $4M | $3M | · | |
| Amort. of Intangibles | $2M | $1M | $1M | |
| Other Non-cash | $38M | · | · | |
| Operating Cash Flow | $-1M | $6M | · | |
| Investing Cash Flow | $-9M | $-395.0K | · | |
| Stock Issued | · | · | $15M | |
| Financing Cash Flow | $9M | $-3M | · | |
| Net Change in Cash | $-2M | $3M | · |
Profitability 8
| Metric | Trend | Q1 2026 | Q1 2025 | Q2 2024 |
|---|---|---|---|---|
| Gross Margin | 298.4% | · | · | |
| Operating Margin | -373.5% | · | -95.4% | |
| Net Margin | -530.0% | · | -229.6% | |
| Pretax Margin | -530.0% | · | -229.6% | |
| EBITDA Margin | -340.2% | · | -95.4% | |
| ROA | -24.5% | · | -32.5% | |
| ROE | 19.8% | · | 36.8% | |
| ROIC | · | · | 7.3% |
Liquidity & Solvency 3
| Metric | Trend | Q1 2026 | Q1 2025 | Q2 2024 |
|---|---|---|---|---|
| Current Ratio | 0.1 | · | 0.2 | |
| Quick Ratio | 0.0 | · | 0.2 | |
| Interest Coverage | · | · | -27.4 |
Efficiency 3
| Metric | Trend | Q1 2026 | Q1 2025 | Q2 2024 |
|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.1 | |
| Inventory Turnover | 4.5 | · | 1.4 | |
| Receivables Turnover | 0.8 | · | 0.5 |
Valuation (TTM) 8
| Metric | Trend | Q1 2026 | Q1 2025 | Q2 2024 |
|---|---|---|---|---|
| Revenue TTM | $34M | · | $50M | |
| Net Income TTM | $-374M | · | $-124M | |
| Market Cap | $57M | · | $8.20B | |
| P/E | -0.2 | · | -4.0 | |
| P/S | 1.7 | · | 164.2 | |
| P/B | -0.2 | · | -38.2 | |
| P / Cash Flow | -51.1 | · | · | |
| Earnings Yield | -572.5% | · | -24.9% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 78 filers · $4.5M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 12 (+7 vs prior Q) | 10 (0 vs prior Q) | 11 (+2 vs prior Q) | 6 (-7 vs prior Q) | +114K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
Company insiders 15 insiders · 4 officers · 11 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Henry Ji | Exec Chair, CEO and President | April 17, 2026 S | 320,161 | 1 | 1 | $390,000 |
| Jaisim Shah | Chief Executive Officer and President | Dec. 18, 2024 P | 139,333 | 0 | 0 | $0 |
| Stephen Hoi Ma | CFO, COO and Secretary | April 17, 2026 P | 22,840 | 1 | 0 | $97,500 |
| Elizabeth Czerepak | Executive Vice President, Chief Business Officer and Chief Financial Officer | Jan. 17, 2023 A | — | 0 | 0 | $0 |
| Jay Chun | Director | Oct. 8, 2025 A | 112,500 | 0 | 0 | $0 |
| Dorman Followwill | Director | Oct. 8, 2025 A | 2,300 | 0 | 0 | $0 |
| Yue Alexander Wu | Director | Oct. 8, 2025 A | 25,000 | 0 | 0 | $0 |
| David Lemus | Director | Oct. 17, 2024 P | 2,000 | 0 | 0 | $0 |
| Annu Navani | Director | Aug. 16, 2024 A | — | 0 | 0 | $0 |
| Tien-Li Lee | Director | Jan. 17, 2023 A | — | 0 | 0 | $0 |
| Laura Hamill | Director | Jan. 17, 2023 A | — | 0 | 0 | $0 |
| Tommy G Thompson | Director | Jan. 17, 2023 A | — | 0 | 0 | $0 |
| Scilex Holding Co | 10% owner | Dec. 30, 2025 S | 244,445,260 | 0 | 3 | $-12,806,953 |
| SCLX Stock Acquisition JV LLC | 10% owner | Jan. 21, 2025 J | 51,039,214 | 0 | 0 | $0 |
| Sorrento Therapeutics, Inc. | 10% owner | Sept. 21, 2023 S | 1,917,210 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Scilex Holding Company, Scilex, Inc. ×2 filings | Sept. 26, 2025 | 79.89% | Initial filing | — | SEC |
| SCLX Stock Acquisition JV LLC ×4 filings | April 25, 2024 | — | Initial filing | — | SEC |
| Sorrento Therapeutics, Inc. ×4 filings | Sept. 26, 2023 | — | Initial filing | — | SEC |
| Sorrento Therapeutics, Inc . | Jan. 23, 2023 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 4 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.